*Review* **Endoscopic Double Stenting for the Management of Combined Malignant Biliary and Duodenal Obstruction**

**Tsuyoshi Takeda, Takashi Sasaki \*, Takeshi Okamoto and Naoki Sasahira**

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan; tsuyoshi.takeda@jfcr.or.jp (T.T.); takeshi.okamoto@jfcr.or.jp (T.O.); naoki.sasahira@jfcr.or.jp (N.S.)

**\*** Correspondence: sasakit-tky@umin.ac.jp; Tel.: +81-3-3520-0111; Fax: +81-3-3520-0141

**Abstract:** Periampullary cancers are often diagnosed at advanced stages and can cause both biliary and duodenal obstruction. As these two obstructions reduce patients' performance status and quality of life, appropriate management of the disease is important. Combined malignant biliary and duodenal obstruction is classified according to the location and timing of the duodenal obstruction, which also affect treatment options. Traditionally, surgical bypass (gastrojejunostomy and hepaticojejunostomy) has been performed for the treatment of unresectable periampullary cancer. However, it has recently been substituted by less invasive endoscopic procedures due to its high morbidity and mortality. Thus, endoscopic double stenting (transpapillary stenting and enteral stenting) has become the current standard of care. Limitations of transpapillary stenting include its technical difficulty and the risk of duodenal-biliary reflux. Recently, endoscopic ultrasound-guided procedures have emerged as a novel platform and have been increasingly utilized in the management of biliary and duodenal obstruction. As the prognosis of periampullary cancer has improved due to recent advances in chemotherapy, treatment strategies for biliary and duodenal obstruction are becoming more important. In this article, we review the treatment strategies for combined malignant biliary and duodenal obstruction based on the latest evidence.

**Keywords:** biliary obstruction; duodenal obstruction; double stenting; anti-reflux metal stent; lumenopposing metal stent

### **1. Introduction**

Periampullary cancers, including pancreatic cancer, biliary tract cancer, duodenal cancer and ampullary cancer, are often diagnosed at advanced stages and can cause both biliary and duodenal obstruction. Biliary obstruction may lead to cholangitis or liver dysfunction, whereas duodenal obstruction may present with decreased oral intake, nausea and vomiting. These two obstructions reduce patients' performance status and quality of life and may deprive them of the opportunity to receive antitumor treatment. Therefore, appropriate treatment and management are very important.

Traditionally, double surgical bypass (gastrojejunostomy and hepaticojejunostomy) has been performed for the treatment of combined biliary and duodenal obstruction in patients with unresectable periampullary cancer [1–3]. Endoscopic double stenting (transpapillary stenting and enteral stenting) has become the standard treatment due to its lower invasiveness and shorter recovery time [4]. Percutaneous transhepatic biliary drainage (PTBD) has been widely used as an alternative treatment after failed endoscopic retrograde cholangiopancreatography (ERCP), but it has disadvantages such as skin infection, pain and decreased quality of life. Recently, endoscopic ultrasound (EUS)-guided procedures have emerged as a novel platform and have been increasingly utilized in the management of biliary and duodenal obstruction. As the prognosis of periampullary cancer has improved due to recent advances in chemotherapy, treatment strategies for biliary and duodenal obstruction are becoming more important. In this article, we review

**Citation:** Takeda, T.; Sasaki, T.; Okamoto, T.; Sasahira, N. Endoscopic Double Stenting for the Management of Combined Malignant Biliary and Duodenal Obstruction. *J. Clin. Med.* **2021**, *10*, 3372. https://doi.org/ 10.3390/jcm10153372

Academic Editors: Do Hyun Park and Stanley W. Ashley

Received: 24 June 2021 Accepted: 28 July 2021 Published: 29 July 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

the treatment strategies for combined malignant biliary and duodenal obstruction based on the latest evidence.

### **2. Classification of Combined Malignant Biliary and Duodenal Obstruction**

Combined malignant biliary and duodenal obstruction has been classified according to the location and timing of the duodenal obstruction (Table 1) [5]. First, duodenal obstruction can be categorized into three types based on the location relative to the major papilla: type I, duodenal obstruction proximal to the major papilla; type II, duodenal obstruction involving the major papilla; and type III, duodenal obstruction distal to the major papilla. Double stenting is most technically challenging in patients with type II obstruction because transpapillary biliary access is difficult, if not impossible [5]. Transpapillary biliary stenting may not be difficult in patients with type I obstruction if the scope can pass through the duodenal stricture after dilation of the duodenal stricture or placement of a duodenal stent [6,7]. Transpapillary biliary stenting in patients with type III obstruction may also be easy to manage because the major papilla is located proximal to the duodenal stricture. However, these types face a risk of duodenal-biliary reflux [8]. Such patients are good candidates for EUS-guided biliary drainage (EUS-BD) [9–12].

**Table 1.** Classification of combined malignant biliary and duodenal obstruction.


Second, biliary obstruction can be classified into three groups according to the timing of duodenal and biliary obstruction: group 1, biliary obstruction occurring before the onset of duodenal obstruction; group 2, biliary obstruction occurring simultaneously with duodenal obstruction; and group 3, biliary obstruction occurring after the onset of duodenal obstruction. Group 1 is the most common, followed by group 3 and group 2. In group 1, the type of previously inserted biliary stent could affect the treatment strategy. The introduction of covered biliary self-expandable metallic stents (SEMS) has broadened the range of treatment options available due to its removability. Both classifications are important in determining the optimal management strategy for combined biliary and duodenal obstructions.

Combined biliary and duodenal obstruction also occurs in patients with surgically altered anatomy. However, evidence is scarce in this area. One study proposed a new classification for malignant afferent loop obstruction according to the location of the intestinal stricture in relation to the major papilla or bilioenteric anastomosis [13]: type 1, obstruction site located distal to the major papilla or bilioenteric anastomosis; type 2, obstruction site involving the major papilla or bilioenteric anastomosis; and type 3, obstruction site located between bilioenteric and pancreaticoenteric anastomoses. Recently, enteral stenting employing the through-the-scope technique with a short-type balloon-assisted enteroscope and SEMS with a 9-Fr delivery system has become possible [13–16]. Nevertheless, endoscopic biliary stenting remains technically demanding due to difficulties in achieving biliary access. A combination of PTBD or EUS-BD may be required in these situations.

### **3. Treatment Options for Combined Malignant Biliary and Duodenal Obstruction**

### *3.1. Surgical Approach*

Traditionally, double surgical bypass (gastrojejunostomy and hepaticojejunostomy) has been performed for symptomatic treatment of unresectable periampullary cancer [1–3]. However, it has recently been substituted by less invasive endoscopic procedures due to its high morbidity and mortality. A recent systematic review and meta-analysis reported that endoscopic double stenting was associated with higher clinical success (97% vs. 86%) and less adverse events (13% vs. 28%), but with a more frequent need for reintervention (21% vs. 10%) compared with double surgical bypass [17]. Even though endoscopic double stenting has become the standard treatment for combined biliary and duodenal obstruction [18], minimally invasive surgical procedures such as laparoscopic gastrojejunostomy are still favored in patients with a long life expectancy, due to reports suggesting better long-term outcomes [19–21]. On the other hand, data on the efficacy of endoscopic duodenal stenting for patients with long life expectancy are also increasing [22–24]. In addition, EUS-guided gastroenterostomy (EUS-GE) has recently been developed as a novel technique for the management of gastric outlet obstruction, with promising results [25–28]. Further research is needed to determine the optimal management for this population.

### *3.2. Percutaneous Approach*

PTBD including percutaneous transhepatic biliary stenting is a well-established rescue procedure for the palliation of malignant biliary obstruction [29], especially when the endoscopic transpapillary approach is not possible. However, this procedure carries high morbidity. EUS-BD is currently gaining wide acceptance among experienced endosonographers. A multicenter randomized trial reported that procedure-related adverse events were significantly higher in PTBD than in EUS-BD (31.2% vs. 8.8%), with similar efficacy [30]. EUS-BD may be preferrable when transpapillary biliary stenting is unsuccessful, if expertise is available.

### *3.3. Endoscopic Approach*

Endoscopic double stenting is the current standard treatment for combined biliary and duodenal obstruction. For malignant biliary obstruction, transpapillary biliary drainage via ERCP and EUS-BD are the two major treatment options. Studies reporting outcomes of endoscopic double stenting including at least 10 subjects are summarized in Table 2. We reclassified biliary drainage procedures that required percutaneous techniques, including PTBD rendezvous technique and percutaneous transhepatic SEMS insertion, as technical failures with respect to endoscopic biliary drainage. In general, the technical success rate was greatly influenced by the biliary drainage method and the proportion of type II obstructions. A systematic review and meta-analysis found that ERCP was associated with similar clinical success and less adverse events (3% vs. 23%) compared to EUS-BD for biliary drainage as part of double stenting [17]. As a result, ERCP remains the preferred treatment option when transpapillary biliary access is possible. While EUS-BD is generally considered a salvage technique for difficult or failed ERCP [31,32], two recent randomized controlled trials reported similar adverse event rates (21.2% vs. 14.7%) in expert hands [33,34].

EUS-BD is especially useful in patients with type II obstruction because transpapillary biliary access is difficult. A retrospective study reported that the technical success rate of EUS-BD was significantly higher than that of transpapillary biliary drainage (95.2% vs. 56.0%) in pancreatic cancer patients with an indwelling duodenal stent [35]. Furthermore, duodenal obstruction has been reported as a risk factor for early transpapillary biliary SEMS dysfunction due to duodenal-biliary reflux [36,37]. Therefore, these two situations are good indications for EUS-BD. The two major EUS-BD techniques are EUSguided hepatico-gastrostomy (EUS-HGS) and choledocho-duodenostromy (EUS-CDS). A retrospective study comparing the efficacy and safety of EUS-HGS with EUS-CDS suggested that EUS-HGS may be superior to EUS-CDS, with longer stent patency (biliary stent patency: median 133 days vs. 37 days) and fewer adverse events [38]. EUS-CDS was particularly associated with reflux cholangitis, probably due to the closer distance between the duodenal stent and the bilioduodenal fistula relative to EUS-HGS. A recent multicenter randomized controlled study comparing the efficacy and safety of EUS-HGS with EUS-CDS demonstrated that the clinical success, stent patency and adverse events

were similar between the two procedures [39]. In summary, disadvantages of EUS-CDS include susceptibility to duodenal-biliary reflux and difficult access in type I obstruction, while those of EUS-HGS include the inability to puncture a non-dilated left intrahepatic bile duct and SEMS occlusion due to bile duct hyperplasia.


**Table 2.** Results of endoscopic double stenting for combined malignant biliary and duodenal obstruction.

*N*, number; ERCP, endoscopic retrograde cholangiopancreatography; EUS-BD, endoscopic ultrasound-guided biliary drainage; EUS-GBD, endoscopic ultrasound-guided gallbladder drainage; PS, plastic stent; SEMS, self-expandable metallic stent; NA, not available.

### *3.4. Novel Types of Stents*

### 3.4.1. Anti-Reflux Metal Stents

Several types of anti-reflux metal stents (ARMS) have been made to prevent duodenalbiliary reflux [50–56]. Although ARMS was associated with a lower rate of stent occlusion compared to conventional SEMS in several studies on distal malignant biliary obstruction, the results were inconsistent and stent patency rates were low. Recently, two retrospective studies showed that a novel duckbill-type ARMS was more effective in preventing duodenal-biliary reflux than conventional SEMS [57,58]. ARMS may be effective not only for transpapillary biliary stenting, but also for EUS-CDS in patients with combined biliary and duodenal obstruction [59]. Prospective studies are needed to further evaluate the efficacy and safety of AMRS especially in the setting of combined biliary and duodenal obstruction.

#### 3.4.2. Lumen-Apposing Metal Stents

Lumen-apposing metal stents (LAMS), designed for transluminal drainage of nonadherent lumens, were first reported by Binmoeller and Shah in 2011 [60]. Although this stent

was initially created for drainage of pancreatic fluid collections, use of LAMS has been reported in gallbladder drainage, biliary drainage (EUS-CDS) and the creation of gastrointestinal fistulae [61]. Recently, a retrospective study reported the technical feasibility of LAMS insertion through the mesh of an indwelling duodenal stent with a technical success rate of 95.6% in 23 patients [49]. Prospective studies with larger sample sizes are needed to further evaluate these LAMS applications.

### *3.5. EUS-GE*

EUS-GE using LAMS has recently received attention as a new alternative for the treatment of gastric outlet obstruction. Several techniques including the direct technique, the device-assisted technique and EUS-guided double balloon-occluded gastrojejunostomy bypass have been reported [62–66]. Each technique involves the LAMS being placed between the stomach and the small intestine distal to the obstructed bowel under EUS and fluoroscopic guidance. Limitations of the traditional approaches (surgical bypass and enteral stent placement) include surgical morbidity and risk of stent occlusion due to tumor ingrowth/overgrowth. Potential advantages of EUS-GE over traditional approaches include less invasiveness (versus surgery) and longer stent patency (versus enteral stent placement). An international, multicenter, retrospective study comparing EUS-GE with laparoscopic GE showed that EUS-GE had similar technical and clinical success rates with reduced time to oral intake, shorter hospital duration and fewer adverse events [67]. A systematic review and meta-analysis comparing EUS-GE and enteral stenting showed that EUS-GE was associated with a significantly lower rate of reintervention despite a comparable technical/clinical success and safety profile [68]. A systematic review and meta-analysis comparing EUS-GE with surgical bypass and enteral stenting demonstrated that EUS-GE was associated with improved outcomes compared to enteral stenting and with shorter hospital stays compared to surgical bypass.

Several case reports have also described the efficacy of EUS-GE in combination with EUS-BD for the management of combined biliary and duodenal obstruction [69–71]. Important advantages of these EUS-guided procedures are the ability to bypass the tumor, reducing the risk of stent occlusion due to tumor ingrowth/overgrowth. Thus, a combination of EUS-BD and EUS-GE may become the optimal procedure for combined biliary and duodenal obstruction in the future. However, several issues remain unresolved. First, EUS-GE is technically challenging, requiring considerable expertise in both EUS and ERCP. Second, development of dedicated accessories and standardization of the procedure are needed for widespread use. Third, EUS-GE may be technically difficult when malignancies invade the fourth part of the duodenum or the jejunum near the ligament of Treitz. Fourth, EUS-GE is contraindicated in patients with significant ascites.

### **4. Treatment Strategies for Combined Malignant Biliary and Duodenal Obstruction**

Based on the above-mentioned evidence, transpapillary stenting and enteral stenting is currently the standard option, whereas to date, EUS-guided procedures are generally reserved for failed or refractory cases to conventional stenting. EUS-GE is especially reserved for selected specialized high-volume centers with extensive experience.

In type I obstruction, transpapillary stenting is possible if the endoscope can pass through the duodenal stricture or an indwelling duodenal stent. Dilation of the duodenal stricture by a balloon or insertion of a duodenal stent prior to ERCP can facilitate scope insertion. When transpapillary stenting fails, EUS-HGS is the next preferred option. Adding EUS-antegrade stenting to EUS-HGS may allow for longer stent patency [72,73].

In type II obstruction, transpapillary stenting is very difficult because the duodenal obstruction involves the major papilla. Although there are several techniques for transpapillary biliary access including RV techniques under PTBD or EUS guidance, success rates are suboptimal. Furthermore, type II obstruction is reported to be susceptible to duodenalbiliary reflux. Double stenting with EUS-HGS or EUS-CDS using ARMS are potential solutions to overcome this issue.

In type III obstruction, transpapillary stenting is not hindered by duodenal obstruction, which is located distal to the major papilla. As with type II obstruction, type III obstruction is reported to present a high risk of duodenal-biliary reflux. Transpapillary stenting using ARMS may be preferable in this context. EUS-HGS or EUS-CDS using ARMS are also possible alternatives in this scenario.

### **5. Conclusions**

Endoscopic double stenting (transpapillary stenting and enteral stenting) is the current standard of care for combined biliary and duodenal obstruction. However, reports on the usefulness of EUS-guided procedures have recently been increasing. An important advantage of EUS-guided procedures is the ability to create a fistula away from the obstructing tumor. With the development of dedicated devices and standardization of the procedure, EUS-guided procedures including EUS-HGS, EUS-CDS and EUS-GE can potentially become the standard of care treatment in the future. The development of new stent types, including ARMS and LAMS, also plays an important role in the management of combined biliary and duodenal obstruction.

**Author Contributions:** Conceptualization, T.T. and T.S.; writing—original draft preparation, T.T.; writing—review and editing, T.S. and T.O.; supervision, N.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** T.S. has received honoraria from Boston Scientific Japan, Cook Medical, Kawasumi Laboratories, Century Medical, MEDICO'S HIRATA, SUMITOMO BAKELITE, CREATE MEDIC. N.S. has received honararia from Boston Scientific Japan, Cook Medical, Kawasumi Laboratories, Gadelius Medical and consultancies from Gadelius Medical. The other authors declare no conflict of interest.

### **References**

